Key Points
- CEO Eric Venker sold 200,000 Roivant shares at an average $36.31, totaling about $7.26 million. The trade was made under a pre-arranged Rule 10b5-1 plan; he retained 999,154 shares afterward.
- Venker has also sold 200,000 shares in several transactions since August, including sales in late October and September.
- Analysts’ consensus rating is Moderate Buy, with a $46.55 average price target; Roivant’s shares were reported down 4.2%.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $36.31, for a total transaction of $7,262,000.00. Following the completion of the transaction, the chief executive officer owned 999,154 shares in the company, valued at $36,279,281.74. This represents a 16.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Venker also recently made the following trade(s):
- On Wednesday, October 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.59, for a total transaction of $7,318,000.00.
- On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.11, for a total transaction of $7,022,000.00.
- On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.62, for a total transaction of $7,324,000.00.
- On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00.
Roivant Sciences Stock Down 4.2%
Shares of Roivant Sciences stock opened at $36.62 on Friday. The company's fifty day simple moving average is $36.66 and its two-hundred day simple moving average is $31.72. Roivant Sciences Ltd. has a 12-month low of $19.79 and a 12-month high of $42.50. The firm has a market cap of $26.45 billion, a PE ratio of -69.09 and a beta of 1.23.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Roivant Sciences
Institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its stake in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock valued at $295,965,000 after purchasing an additional 1,286,464 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Roivant Sciences by 3.8% during the first quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company's stock valued at $229,507,000 after buying an additional 300,000 shares during the period. Pictet Asset Management Holding SA raised its stake in Roivant Sciences by 20.3% in the third quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company's stock worth $152,597,000 after buying an additional 704,783 shares in the last quarter. Wellington Management Group LLP raised its stake in Roivant Sciences by 179.0% in the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company's stock worth $95,124,000 after buying an additional 1,724,588 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Roivant Sciences by 8.0% in the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company's stock worth $87,638,000 after buying an additional 235,493 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
ROIV has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Stifel Nicolaus started coverage on Roivant Sciences in a research report on Wednesday, September 16th. They issued a "buy" rating and a $51.00 price objective on the stock. HC Wainwright boosted their target price on Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a research note on Tuesday, September 8th. Finally, Guggenheim upped their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $46.55.
View Our Latest Report on ROIV
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.
Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
